Md. Sabir Alam

Dr. Md. Sabir Alam

Shree Guru Gobind Singh Tricentenary University, Gurgaon, India

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
MHM Saquib Hasnain
M Saquib Hasnain
MJMd Noushad Javed
Md Noushad Javed
Md. Sabir AlamMd. Sabir Alam
Md. Sabir Alam
PRPoonam Rishishwar
Poonam Rishishwar
SRSanjay Rishishwar
Sanjay Rishishwar
SBSarwar Beg
Sarwar Beg

16 May 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
AIAbdallah Mohammad Ibrahim
Abdallah Mohammad Ibrahim
LCLalita Chauhan
Lalita Chauhan
ABAditi Bhardwaj
Aditi Bhardwaj
ASAnjali Sharma
Anjali Sharma
FFFaizana Fayaz
Faizana Fayaz
FPFaheem Hyder Pottoo
Faheem Hyder Pottoo
Globally, neurodegenerative diseases cause a significant degree of disability and distress. Brain-derived neurotrophic factor (BDNF), primarily found in the brain, has a substantial role in the development and maintenance of various nerve roles and is associated with the family of neurotrophins, including neuronal growth factor (NGF), neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5). BDNF has affinity with tropomyosin receptor kinase B (TrKB), which is found in the brain in large amounts and is expressed in several cells. Several studies have shown that decrease in BDNF causes an imbalance in neuronal functioning and survival. Moreover, BDNF has several important roles, such as improving synaptic plasticity and contributing to long-lasting memory formation. BDNF has been linked to the pathology of the most common neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease. This review aims to describe recent efforts to understand the connection between the level of BDNF and neurodegenerative diseases. Several studies have shown that a high level of BDNF is associated with a lower risk for developing a neurodegenerative disease.

2 January 2020 in Drug Metabolism Reviews
Verified
Journal Article
Closed access
FPFaheem Hyder Pottoo
Faheem Hyder Pottoo
SSShrestha Sharma
Shrestha Sharma
MJMd Noushad Javed
Md Noushad Javed
MBMd. Abul Barkat
Md. Abul Barkat
HAHarshita
Harshita
Ghulam M. AshrafGhulam M. Ashraf
Ghulam M. Ashraf
The neurological disorders affect millions of people worldwide, and are bracketed as the foremost basis of disability-adjusted life years (DALYs). The treatment options are symptomatic and often the movement of drugs is restricted by a specialized network of endothelial cell layers (adjoined by tight cell-to-cell junction proteins; occludin, claudins, and junctional adhesion molecules), pericytes and astroglial foot processes. In recent years, advances in nanomedicine have led to therapies that target central nervous system (CNS) pathobiology via altering signaling mechanisms such as activation of PI3K/Akt pathway in ischemic stroke arrests apoptosis, interruption of α-synuclein aggregation prevents neuronal degeneration in Parkinson’s. Often such interactions are limited by insufficient concentrations of drugs reaching neuronal tissues and/or insufficient residence time of drug/s with the receptor. Hence, lipid nanoformulations, SLNs (solid lipid nanoparticles) and NLCs (nanostructured lipid carriers) emerged to overcome these challenges by utilizing physiological transport mechanisms across blood–brain barrier, such as drug-loaded SLN/NLCs adsorb apolipoproteins from the systemic circulation and are taken up by endothelial cells via low-density lipoprotein (LDL)-receptor mediated endocytosis and subsequently unload drugs at target site (neuronal tissue), which imparts selectivity, target ability, and reduction in toxicity. This paper reviews the utilization of SLN/NLCs as carriers for targeted delivery of novel CNS drugs to improve the clinical course of neurological disorders, placing some additional discussion on the metabolism of lipid-based formulations.

6 August 2019 in Pharmaceutical Nanotechnology
Verified
Journal Article
Open access
PDF file
SMSupriya Mishra
Supriya Mishra
SSShrestha Sharma
Shrestha Sharma
NJNoushad Javed
Noushad Javed
FPFaheem Hyder Pottoo
Faheem Hyder Pottoo
ABAbul Barkat
Abul Barkat
SASarfaroz
Sarfaroz
Recent advancement in the field of synthesis and application of nanomaterials provided holistic approach for both diagnosis as well as treatment of diseases. Briefly, three-dimensional scaffold and geometry of bioinspired nanocarriers modulate bulk properties of loaded drug at molecular/ atomic structures in a way to conjointly modulate pathological as well as altered metabolic states of diseases, in very predictable and desired manners at a specific site of the target. While, from the pharmacotechnical point of views, the bioinspired nanotechnology processes carriers either favor to enhance the solubility of poorly aqueous soluble drugs or enable well-controlled sustained release profiles, to reduce the frequency of drug regimen. Consequently, from biopharmaceutical point of view, these composite materials, not only minimize first pass metabolism but also significantly enhance in-vivo biodistribution, permeability, bio-adhesion and diffusivity. In lieu of the above arguments, the nano-processed materials exhibit an important role for diagnosis and treatments. In the diagnostic center, recent emergences and advancement in the tools and techniques to diagnose the unrevealed diseases with the help of instruments such as, computed tomography, magnetic resonance imaging etc; heavily depend upon nanotechnology-based materials. In this paper, a brief introduction and recent application of different types of nanomaterials in the field of tissue engineering, cancer treatment, ocular therapy, orthopedics, and wound healing as well as drug delivery system are thoroughly discussed.

1 November 2017 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
Md. Sabir AlamMd. Sabir Alam
Md. Sabir Alam
AGArun Garg
Arun Garg
FPFaheem Hyder Pottoo
Faheem Hyder Pottoo
MSMohammad Khalid Saifullah
Mohammad Khalid Saifullah
ATAbu Izneid Tareq
Abu Izneid Tareq
MJMd Noushad Javed
Md Noushad Javed

14 February 2019 in Current Neuropharmacology
Verified
Journal Article
Open access
PDF file
FPFaheem Hyder Pottoo
Faheem Hyder Pottoo
MJMd Noushad Javed
Md Noushad Javed
MBMd. Abul Barkat
Md. Abul Barkat
Md. Sabir AlamMd. Sabir Alam
Md. Sabir Alam
JNJavaid Ashraf Nowshehri
Javaid Ashraf Nowshehri
MOHAMMAD AZAM ANSARIMOHAMMAD AZAM ANSARI
MOHAMMAD AZAM ANSARI
A burgeoning literature documents the confluence of ovarian steroids and central serotonergic systems in the injunction of epileptic seizures and epileptogenesis. Estrogen administration in animals reduces neuronal death from seizures by up-regulation of the prosurvival molecule i.e. Bcl-2, anti-oxidant potential and protection of NPY interneurons. Serotonin modulates epileptiform activity in either direction i.e administration of 5-HT agonists or reuptake inhibitors leads to the activation of 5-HT3 and 5-HT1A receptors tending to impede focal and generalized seizures, while depletion of brain 5-HT along with the destruction of serotonergic terminals leads to expanded neuronal excitability hence abatement of seizure threshold in experimental animal models. Serotonergic neurotransmission is influenced by the organizational activity of steroid hormones in the growing brain and the actuation effects of steroids which come in adulthood. It is further established that ovarian steroids bring induction of dendritic spine proliferation on serotonin neurons thus thawing a profound effect on serotonergic transmission. This review features 5-HT1A and 5-HT3 receptors as potential targets for ameliorating seizure-induced neurodegeneration and recurrent hypersynchronous neuronal activity. Indeed 5-HT3 receptors mediate cross-talk between estrogenic and serotonergic pathways, and could be well exploited for combinatorial drug therapy against epileptogenesis.